<SEC-DOCUMENT>0001193125-14-264827.txt : 20140710
<SEC-HEADER>0001193125-14-264827.hdr.sgml : 20140710
<ACCEPTANCE-DATETIME>20140710090133
ACCESSION NUMBER:		0001193125-14-264827
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140708
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140710
DATE AS OF CHANGE:		20140710

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		14968359

	BUSINESS ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d755224d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July&nbsp;8, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36177</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1686563</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>401 Professional Drive, Suite 250 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gaithersburg, MD 20879 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(240) 243-1201 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of July&nbsp;8, 2014, the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) of GlycoMimetics, Inc. (the
&#147;<B><I>Company</I></B>&#148;) appointed Dr.&nbsp;Mark Goldberg, M.D. to serve as a director of the Company and a member of the Nominating and Corporate Governance Committee. Dr.&nbsp;Goldberg will serve as a Class III director whose term will
expire at the 2017 annual meeting of stockholders. There is no arrangement or understanding between Dr.&nbsp;Goldberg and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between
Dr.&nbsp;Goldberg and any of the Company&#146;s other directors or executive officers. The Company is not aware of any transaction involving Dr.&nbsp;Goldberg requiring disclosure under Item&nbsp;404(a) of Regulation S-K. Additional information
about Dr.&nbsp;Goldberg is set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mark Goldberg</I></B>, age 60, has served as a member of our Board since July 2014.
Dr.&nbsp;Goldberg has been the Executive Vice President for Medical and Regulatory Strategy of Synageva BioPharma Corp., a biopharmaceutical company, since January 2014 and was the Senior Vice President of Medical and Regulatory Affairs of Synageva
BioPharma Corp. from September 2011 to January 2014. Dr.&nbsp;Goldberg served in a variety of senior management positions at Genzyme Corporation, a biotechnology company, most recently as Senior Vice President, Clinical Development and Global
Therapeutic Group Head, Oncology and Personalized Genetic Health, from 1996 to July 2011. Prior to working at Genzyme Corporation, he was a full-time staff physician at Brigham and Women&#146;s Hospital and Dana Farber Cancer Institute, where he
still holds appointments. He has also been a Clinical Associate Professor of Medicine at Harvard Medical School since 1996. Dr.&nbsp;Goldberg is a board-certified medical oncologist and hematologist. Dr.&nbsp;Goldberg serves on the board of
directors of ImmunoGen, Inc., a publicly held biotechnology company, and served on the board of directors of Synageva BioPharma Corp. within the past five years. Dr.&nbsp;Goldberg received his A.B. from Harvard College and his M.D. from Harvard
Medical School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Company&#146;s compensation policy for non-employee directors, upon his appointment as a director,
Dr.&nbsp;Goldberg was granted a nonqualified stock option to purchase 15,401 shares of the Company&#146;s common stock at an exercise price of $8.86, the closing price of the Company&#146;s common stock on the date of grant. This option will vest
and become exercisable on the last day of Dr.&nbsp;Goldberg&#146;s initial term of office for Class III directors, which will be the date of the 2017 annual meeting of stockholders. Additionally, Dr.&nbsp;Goldberg will be entitled to receive a
$30,000 annual retainer for his service as director and a $3,000 annual retainer for his service on the Nominating and Corporate Governance Committee. At each annual stockholder meeting following which Dr.&nbsp;Goldberg&#146;s term as a director
continues, Dr.&nbsp;Goldberg will be entitled to receive an additional nonqualified stock option to purchase 7,700 shares of the Company&#146;s common stock, which option will vest and become exercisable over a one-year period following the date of
grant. Dr.&nbsp;Goldberg has also entered into the Company&#146;s standard form of indemnification agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;10, 2014, the Company issued a press release
announcing Dr.&nbsp;Goldberg&#146;s appointment to the Board.&nbsp;A copy of this press release is furnished herewith as Exhibit&nbsp;99.1 to this Current Report. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated July&nbsp;10, 2014, &#147;GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors.&#148;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"><B>GLYCOMIMETICS, INC.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian M. Hahn</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: July&nbsp;10, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian M. Hahn</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated July&nbsp;10, 2014, &#147;GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors.&#148;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d755224dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g755224ex99_1pg001new.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: GlycoMimetics</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: Brian Hahn</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: bhahn@glycomimetics.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Phone: 240-243-1207</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLYCOMIMETICS APPOINTS MARK A. GOLDBERG, M.D. TO BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Dr.&nbsp;Goldberg Brings Perspective as Medical Oncologist and Hematologist and Extensive Biopharmaceutical Regulatory Experience to
GlycoMimetics Board - </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GAITHERSBURG, MD, July&nbsp;10, 2014 </B>&#150; GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the addition of Mark A.
Goldberg, M.D. to its Board of Directors. Dr.&nbsp;Goldberg is Executive Vice President,&nbsp;Medical and Regulatory&nbsp;Strategy&nbsp;at Synageva BioPharma Corporation and holds appointments at Brigham and Women&#146;s Hospital and Dana Farber
Cancer Institute. He is also an Associate Clinical&nbsp;Professor of Medicine at Harvard Medical School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A seasoned oncologist, hematologist and
corporate medical/regulatory strategist, Mark is a welcome addition to the GlycoMimetics Board of Directors,&#148; said&nbsp;<U>Rachel King</U>, CEO of GlycoMimetics. &#147;We&#146;ve just initiated the clinical program for our first oncology drug
candidate and are looking forward to advancing additional novel candidates from our pipeline. Mark&#146;s perspective will be very valuable to us, particularly his experience in developing and securing approval for benchmark therapies for rare
diseases.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Goldberg joined Synageva in 2011 from Genzyme Corporation, where he had most recently served as Senior Vice President, Clinical
Development and Global Therapeutic Group Head, Oncology and Personalized Genetic Health. While at Genzyme, he played a central role in the development and approval of medicines such as
Fabrazyme<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Aldurazyme<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Myozyme<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Lumizyme<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and Mozobil<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women&#146;s Hospital and Dana Farber Cancer
Institute. Dr.&nbsp;Goldberg received his A.B. (magna cum laude) from Harvard College and his </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
M.D. (cum laude) from Harvard Medical School. He holds Board appointments at Immunogen Corporation, Idera Pharmaceuticals and the American Cancer Society, New England Division. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I&#146;m excited about the opportunity to join the GlycoMimetics Board of Directors,&#148; said Dr.&nbsp;Goldberg. &#147;As an oncologist and
hematologist, it&#146;s encouraging to see a biotechnology company developing novel drug candidates for unmet medical needs such as sickle cell disease and many forms of cancer.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About GlycoMimetics, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics is a clinical
stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the
structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit
disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note on Forward Looking
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statements in this press release about future expectations, plans and prospects for GlycoMimetics, including statements about its
strategy, its future operations, clinical development of its therapeutic candidates, timing of the availability of data from clinical trials, potential therapeutic utility for its product candidates, market opportunities for its product candidates,
its plans for potential future product candidates and other statements containing the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148;
&#147;predict,&#148; &#147;project,&#148; &#147;target,&#148; &#147;potential,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;continue,&#148; and similar expressions, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: availability and timing of
data from ongoing clinical trials, the uncertainties inherent in the initiation of future clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be
indicative of the results of future trials, expectations for regulatory approvals, availability of funding sufficient for GlycoMimetics&#146;s foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that
could affect the availability or commercial potential of GlycoMimetics&#146;s therapeutic candidates and other </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
factors discussed in the &#147;Risk Factors&#148; section of GlycoMimetics&#146;s Quarterly Report on Form 10-Q that was filed with the U.S. Securities and Exchange Commission on May&nbsp;9,
2014, and other filings GlycoMimetics makes with the Securities and Exchange Commission from time to time. In addition, the forward-looking statements included in this press release represent GlycoMimetics&#146;s views as of the date hereof.
GlycoMimetics anticipates that subsequent events and developments may cause GlycoMimetics&#146;s views to change. However, while GlycoMimetics may elect to update these forward-looking statements at some point in the future, GlycoMimetics
specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing GlycoMimetics&#146;s views as of any date subsequent to the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g755224ex99_1pg001new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g755224ex99_1pg001new.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``("`@("`0("
M`@(#`@(#`P8$`P,#`P<%!00&"`<)"`@'"`@)"@T+"0H,"@@("P\+#`T.#@\.
M"0L0$1`.$0T.#@[_VP!#`0(#`P,#`P<$!`<."0@)#@X.#@X.#@X.#@X.#@X.
M#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@[_P``1"`!.`7P#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]_***J7^H6&E:-<ZCJ=[!IVGV\9DN+FYE6.*)1U9F8@`#U-`%NN*\
M>_$;P1\,/`%UXH\>^);'PSHL"Y:>]G";SV5!U9CT``)K\]OC5_P47T:U\9O\
M-_V:O#<_Q@^(4[F"*\MK=Y+&%\X)0+\TV#W&%[Y(KYPO?V=M=\1^)[#XG_MY
M_%.^U+6;H>;I'PWT6;SKV89R(Q''\L2]`=HQ_><&J46W9`[)7>B/<I/^"K'P
MR'QZ^P1^!M;D^%JOY#^*_+(<2YX?R<?<QVSO]J_2+X??$OP+\4_`%MXG\`>)
MK'Q-HTPXFLY@QC/=77JK#N"*_.5/%]O'\.QX0@_9Y\'K\%?+$;>!Y$']INN,
M>>9_N>?C^'K_`--*\&MOV==1TKQE>_$O]@_XH7_A[Q+:DS:M\-==N#;WD('5
M`C_+,F<@;@5]'-==;"8C#I.K!I,Y*.+PN);5*:;7;^OQ/W,HK\N?@S_P45LH
M_&B?#7]I[PO<?";Q_;N()=0FMGCLIGZ`NK?-%GUY4]<@5^G&FZGIVLZ#::II
M%_;ZGIMU&)+:ZM9EDBE0]&5E)!'TKC.RQ>HHHI""BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@#YI_:C_:4T']F/X"VGB_5]#O/$=]J5]]@TFPM2%$
MMP8V<!W/W5PIYP?2OS(UOPA^TE^U=I4?C_\`:4\>Q_`#X`^:)K710QADN8SR
M!'!]Z1R,X:3<W7"XKWG_`(*N\?LM_"+_`+'Z+_TGDK>^,%O#JO[9&DQZFGV^
M'3/AUI%QI\5PQ>.VEEFNA)(J'Y0[!$!;&?E%=V#PSQ>(C13M?_*YQ8S%+!86
M5=J]O\TCB/!-QX9^''@MO#'[-/@>/X=:+*FR]\=Z[:+-K>I]BT2/G8IY(9^,
M$85:FTW0;+3M3NM3>6XU;7;L[K[5]2G:XO+IO5Y&R?H.@K;)R<FBOU/!Y;A<
M&KP5Y=WO_P``_(\=FN+QSM-VCV6W_!^85BZIH%AJE]:W[&?3]9M&WV6JV$S0
M7EJWJDJX8?3I6U17J3A"I%QFKIGD4ZDZ4U.#LUU1SWC&YT'X@>"X_"_[2/@F
M+XH:!&ACLO&^D6JPZ[I8Q@/*JX\P#C+)Z<AJ\AT3P-^T9^RYIDOQ!_99^("?
M'CX'%_.O/#\C&:2V3.2LEOG<CX'+(%8#M7O_`$/%=5\#K6#2_P!NS2FTU/L`
MU+P]?MJ"6[%$N61HMC.H^4L-Q^;&>:^"S3**5"E*O1=DMU_D?HN49W6Q%:.'
MK*[>S]%U1]`?LK?M/:%^T_\`!;4O$>FZ#=^&=7TB\%EK&GW)#I'-L#9C<?>4
M@]P".E?45?DK_P`$H?\`DDOQQ]?^$T/_`**6OU>U#4+'2M%NM2U.\AT_3[:,
MR7%S<2!(XE'5F8\`5\0?>/<N45\-^*/^"B7[,/ASQ/=:1:>*=1\7W=O)LF?P
MYHL]]"N.O[Q%VGGCK7I/PH_;"_9\^,OB5=#\&^/8$\0L<1Z1JT+V-W(>X6.4
M`G\*069]-T5YK\6_BMX4^"WP2U'Q_P"-'N8]`LI8HYFM+<S29D<(N%')Y-=M
MH>KV?B#P7I&O:>7-AJ5E%=VQ==K&.1`ZY'8X(XH$:E%%%`!1110`4444`%%%
M<.OQ%\)/\1#X674O^)T)S`8?*;&\?PYZ5K"E4J7Y$W;5V[&,ZM*E;GDE?17Z
ML[BBD9@D;,QPH&2:XKP_\0O"GB?Q)/I.BZC]KO8D9V3RR!M4@$@GKR11&E4G
M%RBFTM_(<JM.$E&4DF]O/T.VHKSGQ/\`%#PQX3\9VFAZI)-]KF"EC'%N6(,>
M"37HD;I+`DD;!D=0RD=P>E.=&K3C&4HM*6WF3"M2J3E"$DW'?R'4445B;A11
M10`445C:_KVF^&O"]QK&K2/%8P8\QDC+D9.!P.:J,93DHQ5VR)2C"+E)V2-F
MBN)B^(/AJ?X5W7C&&YE;1(,AW:!E8G(&`IYZD"I_!WC?1/&^A3WVC/)B&3RY
MHYDVLAQD?I6\L/7C!SE%I)V?D^QA'$X>4XPC--R5UKNNYU]%%%<QU!1110`4
M444`%%>9W?Q>\"67[46E?!RXU5T\?:EILFHVE@+=RKP1C+-OQM&!VS7IE`!1
M110`4444`%%%%`'Y5_\`!5W_`)-<^$7_`&/T7_I/)72?%#_D\T<?\TST/_T?
M>US?_!5W_DUOX1?]C]%_Z3R5TGQ1_P"3S5_[)GH?_H^]KWLF_P"1C3^?Y,\#
M//\`D55/E_Z4C#HHHK]:/QH****`"NR^#G_)\WA;_L7-2_G#7&UV7P<_Y/F\
M+?\`8N:E_.&O$SC_`)%U3Y?FCZ#(_P#D9T_G^3/+_P#@E#_R2/XX>G_":'_T
M4M=#^TM+XE_:;_X*1>'/V3M%UJ[T#X=:/IZZSX[N[)B&NE/*P$CM@;<'C<P/
M:N>_X)0_\DD^.'_8Z'_T4M=7;:_;?!7_`(.*/$I\7,NG:#\4/"T%OHNIW!V0
MF>-PWE;CQDL`O_`A7Y&?L_4^[_A]\%OA7\+?!%IH'@;P+I&AV,$(C\R.R1IY
M@.\DI!=R3SEB:\@^.'[&WP6^-ND)/=>'X?!?C"WE66R\3^'85M+R%@P8D[,!
M\^K<CC!&*^K7!,3!3M8C@^AK\W/B=\//VM_`/PT\9?$#4_VQ]/TKPYI-K/>^
M3+X-C&U`"4BWF3J3M0''4B@DZ?\`;QT7_A'/^".6M:#_`&E>:Q]@ETZW^W:A
M*)+BXVS*-\C`#+'')KJK;]H.7X6^-/V9?AOXA\+JG@_QQX8L[6S\4B^.+>^%
ML@6W>+9CYR4`;?W/'%?'7CGQE\2_B%_P;5WGC/XJ:H^L^(]6UN*XM[R2W6$R
M6ANU$)VJ`.@-?67QS^$$_P`7_P#@D/X7M-%1AXT\/^&M.USPU-$/WJ75O;(X
M5".077<@]V%`S[/\0Z[IOA?P'K/B36;@6NE:792WEY*?X(XT+L?K@=*^=O@Q
M^TA#\0_V,M6^.?CG0(/AKX+@FN)+.:XOS,9[.)B!<ME$V[\?*HSUZU\2_%+]
MHF__`&BO^">_P.^$_@^YV_$;XK7\>D^)(;=@)+"&U8"]<CJH+(67U"D=Z],_
M;I\-Z;X!_P"";'PP^'NFJ^G>`+7Q-I.F:HL`VI]E611AO0,<Y!X.:`L;.F_M
M9?M#?%H7&L_L_?LU2Z[X#60BS\0>)]933_MZJ?O11-C(."`03UYQC%>@_"3]
MKC4/$/[1=O\`!CXT_"_4O@U\4KJ)I-,M;B;[58ZF%!)\F=0`3@$]QP1DD5]?
MZ#9:/IW@C2+#P_%!!H5O9Q1Z?';8\I80H";<=MN,5/-I6F7.O6FJ7&GVT^IV
MJ.EM=20JTL*OC<%8C*@X&<>E`M#Y@_:(_:IT+X'ZYH?@S0_#-_\`$KXLZZN=
M&\*:3GS77./,E8`[%_`GOC'->#ZK^UK^T_\`#/2AXO\`C/\`LJ3:/\.?,5KS
M4-!UZ.]N=.A.,O)$N<X&2=VS\*7X"V^FZO\`\%U?VH=4\2%;KQ=IEK;V^ABZ
M0;[>Q)QF+/0'H2.U?HQJ-I97^@7MEJ4$=SI\\#1W,4R!D=",,"#P1B@>B.;\
M"^/O"GQ(^$&C^._!VK1:QX9U.V\^VNHCV_B5AU5E((*GD$$5\$WVM71^*UYX
MBC++.NI&XW#L0_K^%9G[#=[#H7[+?[2=GH<[3^!=)\>ZG!X8FS\@A\M0H3_9
MR5/U)KU7P7X1;Q!^SGXYU'RB][%*CVQ`Y8H-S`?F:^RR65.A2J5:FS<8_>_^
M"?#9]&I7K4Z-/=*4ON6GY'TEXX\90V?[-=SX@M90LM_9*EL4;D/(,<?[N3^5
M?+GP8OWT_P#:&T96)072O"Y(QD%"P_516+/XEU'Q%\._"W@B-7<VMVPC&>'W
MG"`?3+?G7?\`CK2(_`_[0/@F2V7$$5O:%FZ;BC;'_$@?K7K4,)#"49X5_%4Y
MK>BV_P`SQJ^,GC*]/%KX:7)?U>K_`,CLOB]<^&;;XY>'DU3PT^IWDJQ_OTOS
M$"/,"@,NTYQ]17<?$#XJ_P#"OO%6G:2-"%];2P!_,%QL*`'&`-IS@>]>5?&]
M@_[0'A%QT:*$CC_IL*3X]P+<?&OPY`^0LD"JWH07KSZ&&HUUAHU4VG&6EWT^
M>GR/1KXJO0EBIT6DU**V77Y:_,V+S]HJ\BU));?PF1I+L1')/.5:4>HXQ^'-
M:VM?M!6OEPIX6T*?5I#"))WFRJPY&2N`#G'KP*Z?XR:7I]O^S/>0P6D4<5H8
M?LRK&/W>&"\>G!(K.^`.G62_!2:Z-O&UQ<WD@F8H"6`.T`^V.U<ULM>"^M*C
M\+Y;<SU\V=5\T6.^J>V^*/-?E6GDC?\`AK\5+3Q\UU936/\`9FK6Z>8T0DWK
M(G3<IX[]JH>//C)IWA/Q"=#TRP?7-:&!)&C;4C)Z*2`23["O)OA3`EI^UEXA
M@MUVI&+D(N.GS'`KA]!3QA>?'S6Y_#`MV\1+<3N?M2(V/G^;:'R,_3G&:Z?[
M-PGUN<K>Y&*E9NRU[O>QR?VIC?J<(WO.4G&Z5W9=EM?4]ETWX^W-MXA@L_%_
MA>71H9<?OE+90'N58#(]P:N?'/QCY/P^L]&L[$7]CK%OYRWZ2';&%92.,<YS
MZBN*\2^%OC9XLTB*Q\0065Y`D@>/]W#&ZM[,!G\*ZS6M(UC1/V&[K2]>B6._
MM<(HW!MJ;P1S^=+V.!IUZ-6'+S<R3C&3:UV??1]-BO;X^KAZU*IS<O*VI2C9
MZ;KMJNNYPO@'Q9;S?`SQ%X2U/PX=1TNVL);QY?M!3S2'3"C"\$$@YYZ=*]:^
M"=[X?'PDU.^T[3/["M(KMC<M/=^<SX4'<S8&,#C&.U<?X45?^&#-<;9EMDW*
MCGJ*Y/PS-<6_[#GB]K8L"U_MD:/J%(7)-:XBE#$1JQC[MZB6[MTN[;&.&JU,
M-.E*7O6IM[*_DK[G<:]^T+#%K,MGX8T)M51"0+B5RH;'<*`3CW-:_@WXZV6O
M>*K?1-<TA]%O9W\N&17+H6/0$$`KGIWH_9_T[11\*)[^&**75GNG2Z=@"Z`?
M=7V'\Z]F&D:#_P`)8;\6%G_;0BYE\M?."9QGUQ[UY&*EEU"4\.J+O'3FOK?O
MVL>SA(YG7A#$NLK2UY>72W:^]SR_XC?%Z+P9XBAT/3--_M?6&0-*C.56(,/E
M'`R2>N*F^&_Q5?QOK5WI5[HDNF:A;Q[V9-SQ_0G'RGV-<U\5/AOK&I^/;?Q=
MX2ND778XU,EJ9`LC[!@.F>O&!BF_"KXCWFH^.[OPOXFTN*R\1/G?=1P")YF0
M<K(!W`Z&M/J^$GEG/1AS22O)WU3ZZ;-&:Q.,AFG)6GRP;M%6T:Z:]&?15%%%
M?*GUY^</BC_E9=^&'_9/-0_]%&MOX@_MV6W@']L_QQ\&'^&6I>)O$&G00IX=
MAT:X,USK-U*JL(S'LQ$BAB2^XX"]*Q/%'_*R[\,/^R>:A_Z*-8OPJT+2]1_X
M.0/CUK%[:I<WVF>%H&L7=0?(9Q;HSKZ':2N?0FF4;>N_M<?M"?"673/%/Q\_
M9P3PG\+[V[C@N=7T;7DOI])#\!ID4'([G.WT&3Q7W1XA^(?@_P`*_`Z\^(^N
MZU#8^#K;3A?RZ@QRODE0P('4D@C`ZY->2?M?:=:ZK_P3/^,EE>1B6!O#TCE2
M.Z,KJ?S45\`?'6^N;S_@C#^R98:U=SKX0U75-(B\3R@DJ\(P5#^Q;`P:!;GO
MNG?M5_M'_%6%]?\`@-^S)+J_@#S/]#UOQ3K<>G/J*@\F*)L?*<'#9(YYKT/X
M.?M:7OB[]H3_`(4U\8/AEJ7P;^*LD+36%A=3?:;/4D498P3A0&.`3CD8!Y.*
M^O\`2;+3=-\+Z=I^C00VVD6]LD5E%;`")(E4!`N.,8QBEETO3)]?M=4GT^VF
MU2WC9+>[>%3+$K8W!6(R`<#.*`+]%%%(1^5?_!5X@?LM?"(D@`>/8B23_P!.
M\E;_`,9Y&T+]HS0O%VIV\T'A#5O`6E6%GKJQE[$W,,MR[Q-*N0C;94(SP>>>
M*^Q_CU\`/`'[17P;7P;X_MKAK:WN/M.G7EI,8YK*?:4$B=CPQ&"""#7Y;:QX
M`_:X_8CAOE\.E/V@_P!GEB?MFB7]N;H06_4J\+;FBXZE=T8QR.:[<)B)82O&
MM%7:_P"&.3%X:&,PTJ$G9/\`SN>THZ20I)&ZR1N,HZ'*L/4$=:=7GGPS\5_!
MSXWVPN?@'XKB^&_CQ@7O?AAXLN"+2>3JWV20Y*$G.`N1R!M2NJDU.\TGQ@?#
M'C'1;OP7XI49&GZD`%G`_B@E'R3+[J3C/-?IV#S7"XSW;\LNS_1]3\HQV38O
M!7E;FCW7ZKI^7F;-%&#G&.:QAJMQJ/BY?#/A/2+OQCXK<`C3-,4.80?XYI#\
MD*^[D5Z]6K2HPYZCLCQ*5&K7FH4HMOR-=V6.)I)&6.-1EG8X"CU)/2NL^`L_
M]O?M96_B?2X9;CPIHFAWL&HZXT>RQCED,96,2MA6.$8G'`]:\6^)GB3X2?!.
MP%W^T'XKA\<^-,;[+X8>$[@M;Q2=5%Y*,,_;@[1UX:N2TCP9^UO^VW8V=O>I
M'^SQ^SMM"6FE6,!MQ<09X"1`*TW!X+;8Z^!S/.(8FFZ%)>Z]V_T_X)^D93D<
M\+46(K2]Y;)?=K_P#T[_`()0$'X1?&_!!'_"9G!'0_N5K[M_:$_9V\#?M%?"
M!?#?BM)-/U6SD\_1-=LP!=Z;-V=#W![KT-3?`#]G;X>?LX?".;PGX!M[EA=S
MBXU._O9C)/>S!0N]NPX```'`]>M>[U\8?;-ZGYGZ9X/_`."B_P`)=&B\,>%_
M$_@SXTZ!:J(["^UZ7[)>)&/NB1VY<@8%17O[-'[3O[1WB+2X_P!J;X@:5X>^
M&UE<I<2>"?"`.+YE.0LTHX9??J,\"OTUHI!<^6_VE_@9J'Q._P""?M_\(/AW
M%8:+(ILTTZ&?]W;PQ02*=O'3Y17O/@[29O#7P1\+:'J4D9GTK1+:TNG4_)NB
MA5&(/IE375US/C/PTGC+X4^(?"DFI7>CPZO82V<MY8N%GA612K,A/1L$X-`C
M\N/V(?A'X2\2_P#!0'X\?M`^'M/,?@>T\07>E^#%?_5[G??<31+T"XVJN.FY
MA7Z7?%#X:>%/B]\#M>^'_C2Q^W:#JL'ERA3AXF'*R(>S*<$&JGPB^%7A?X+?
M`#0?AUX028:+I<;!);E@TT[NQ=Y'(`RS,Q)KTJF-O4_.#PU\-_VZ?@?HZ^"?
MA_XI\(_%OP%9QM%HDWB9VM;ZRBZ(CN/O[1C`''%=]\)_@5\?-4_:ATOXT?M#
M?%)+S5M*MI(=%\(>%RT&F6PD&'\[M*<8^IP>U?<-%(+GQ?\`M`?LQ^)?&'QQ
MT7XX_!'QE'\.OC3I-O\`9VN9X/,L]7@`XAN%'7C@'ICK7E.L^!?^"@_Q4\-O
MX&\7^+O!7PT\,WL9AU?6]`!EO9X2,,L8'^K+#(X]<5^DU%,+GSUH'P'T7X;_
M`+$]M\(/AQ&+>TAC57N;IOWEU(7#R32$=69AGVZ=J[WX:^#+CPE\)AH>J&*:
MZDED:<Q'*L&/`_*O2**ZEB:JP_L%\-[_`#.%X6D\3]8?Q6MY6/FKPE\%+_1/
MC@FN7TMM-HUO<236T2'YL\E,CVX_*NH^+WPXU;QS/HMQHTT$$]J)%E,S8R#@
MKC\<U[;178\RQ<L1&NW[T59=CB65X2.&EATO=D[ON?/GCGX8^)/%'CGPOJUM
M-:QK86T*7(DD.697#''Y5>^)7PVUSQ=\3=%UC3IK=+6T11*LSX)PV>*]UHI0
MS+$P<'&WN)I:=]QSRS"S4T[^^TWKU6QPOQ$\-WWBKX27^AZ>T:7<VS8TK848
M8$_RJI\+_"FH^#?AA'HVIO%)="XDD)A;*X8Y%>BT5R?6:OU;ZO\`9O?YG9]5
MI/%+$?:M;Y'A/@OX:ZYX?^/FK^)[V:W:QN3*8UC;+#><C-4?'7P;O-1\:OXH
M\&:D-(U5V\R6$L4!?^\C#H3WSQ7T)176LRQ2K^V3UM;;1KS1Q_V7A'0]BT[7
MOOJGY,^5H/A/\3M?\16DOBWQ;)';0$$2I=F20#T4#`!]S7M?C;PM>Z[\%+GP
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MK?$Q/%/A7Q$\%P(PJ023&,V^/[AZ8/7![T[X<_"O6-!\?W'B_P`6ZDE]JQ5M
MJJQ<[F&&=V[G%>_45E_:6)^K^PTM:U[:V[7-O[+POUGV^M[WM?2_>Q\_^"[_
M`,0>+_VD_$6OPZA<VOA>P)M5M\X2<KD`8/OEL^XKZ`J&&VM[976W@C@5W+N(
MT"[F/4G'4^]35R8FNJ\TXQY4DDEZ?F=F%H/#TVI2YFVVWZ_DCY(UGX&^+-0_
MX+!^#/CQ#=60\(:5X4NM+N(&<_:#+*FU2!TQ3?`'P,\6>&/^"J_Q<^-=_=64
MGA;Q/HD%G80Q.3.KIY62XZ`?NS^8KZYHKDN=USRSXW>"]4^(O[)?C_P/HDD,
M.K:UI$EI:O<-B-7;&-Q]*\WTK]G?1_$7_!,WPU\`OB=#'?QVWA^&QO)K-\&&
M>,?+-$W9E;!!KZ;HI"/S@\-_#S]N_P""F@1>"/`OBCP?\7?!-FC1:->>)7:U
MOK2+HB2-_'M&,=N,5Z#\(/@)\<;G]J"T^-W[0OQ4&K^)+*R>UTCPKX:W6^E6
M2.,-YBYQ(>_N3D\BOMZBF.Y\A>._`G[3&I_\%*_A_P"+?"/Q!ATOX$V4<?\`
M;V@&8*;C&?,4IC+ECC#9XKZ]HHI""D(#*58`J1@@]Z6B@#X,_:$_8!^$WQEO
MKCQ1X6!^%_Q'#&6+6=&CV0SRYR&FB7`)SR67#>YKXDU[XF_'_P#9MTZ+X:?M
M?_#H?&[X.%A'8>*8@99[89PKQW6,JXXP)-K9X#5^YU9NKZ-I/B#PY=Z/KFFV
MVKZ5=1F.XM+N%98I5(P0588--.S'?2S/R)77_P!FZ7X5CQ_'^TU/!\(L?O/#
MDD8_X219".+0/G?M[;MN<_\`+3O7GFA_%?X[?M"VMQ\-/V,OAK_PIOX2B8QW
M_BZ=?+N+K/#R2W)&=[<DA-SY.":^RY?^":W[,TG[1R^.QH%W'I7^L;PJEP1I
MIEW9W;?O!,<>7G;7W9HNAZ/X<\-6FC:!I=KHVDVL8CM[2S@6**-0,`!5&*WJ
M5ZU9+VDF[=V84Z%"BVZ<4K[V1\+_`+/O_!/WX6?"2^@\5^-V/Q4^)+-YTVJZ
MNF^WAE/),439R<_Q-D_2OOI45(U1%"(HPJJ,`"G45SFP4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
9110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
